Articles tagged with: Dr_ Morris Sherman

Ontario expands patient access to chronic Hepatitis C therapies on public drug plan.

published: March, 06, 2018 Written by // Guest Authors - Revolving Door Categories // Social Media, Hep B and C, Current Affairs, Health, Revolving Door, Media, Guest Authors

Good news for those infected or co-infected with Hepatitis C in Ontario

Ontario expands patient access to chronic Hepatitis C therapies on public drug plan.

- Gilead applauds Ontario’s Ministry of Health for expanding access to curative hepatitis C therapies to all diagnosed patients, regardless of severity of illness - Ontario’s expanded access includes EPCLUSA®, a 12 week treatment for patients with chronic hepatitis C across all six genotypes - Gilead’s new product, VOSEVI™ is now available under the Ontario Drug Benefit Program - The removal of the fibrosis level criterion for access furthers Canada’s commitment to the World Heal